HC Wainwright Estimates Rezolute FY2030 Earnings

Key Points

• HC Wainwright projects that Rezolute will achieve FY2030 earnings of $0.61 per share, maintaining a "Buy" rating and a $14.00 price target, despite the current consensus of a loss of ($0.93) per share.
• Shares of Rezolute are trading around $8.20, experiencing a 52-week low of $2.21 and a high of $8.34.
• Institutional investors hold 82.97% of Rezolute's stock, with several companies, including BNP Paribas and Ameritas, recently acquiring new stakes in the company.

Rezolute, Inc. (NASDAQ:RZLT - Free Report) - HC Wainwright issued their FY2030 earnings per share estimates for shares of Rezolute in a research report issued to clients and investors on Thursday, September 18th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings of $0.61 per share for the year. HC Wainwright currently has a "Buy" rating and a $14.00 target price on the stock. The consensus estimate for Rezolute's current full-year earnings is ($0.93) per share.

Rezolute (NASDAQ:RZLT - Get Free Report) last posted its quarterly earnings data on Wednesday, September 17th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.03).

Several other equities research analysts also recently issued reports on the company. Wedbush reissued an "outperform" rating and issued a $12.00 price objective on shares of Rezolute in a research note on Thursday. Maxim Group increased their price target on shares of Rezolute from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Thursday. Guggenheim reaffirmed a "buy" rating and set a $15.00 price objective on shares of Rezolute in a research report on Monday. Finally, BTIG Research reiterated a "buy" rating and issued a $17.00 target price on shares of Rezolute in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $14.50.

Rezolute Stock Performance

Shares of NASDAQ:RZLT traded up $0.44 during mid-day trading on Friday, hitting $8.14. The stock had a trading volume of 1,082,555 shares, compared to its average volume of 957,667. The company's 50 day moving average is $6.62 and its 200-day moving average is $4.74. Rezolute has a 12-month low of $2.21 and a 12-month high of $8.81. The company has a market cap of $739.20 million, a PE ratio of -8.39 and a beta of 0.03.

Institutional Trading of Rezolute

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Man Group plc acquired a new position in shares of Rezolute during the 4th quarter valued at about $425,000. Cubist Systematic Strategies LLC raised its position in shares of Rezolute by 335.4% in the first quarter. Cubist Systematic Strategies LLC now owns 210,581 shares of the company's stock valued at $611,000 after purchasing an additional 162,216 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Rezolute by 9.0% in the first quarter. Acadian Asset Management LLC now owns 605,042 shares of the company's stock worth $1,752,000 after buying an additional 50,163 shares during the last quarter. OMERS ADMINISTRATION Corp boosted its holdings in shares of Rezolute by 56.4% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 118,900 shares of the company's stock worth $345,000 after buying an additional 42,900 shares during the period. Finally, XTX Topco Ltd acquired a new position in Rezolute in the 1st quarter valued at $95,000. Institutional investors and hedge funds own 82.97% of the company's stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.